Aloanticorpo anti-Diego (a) em gestante

Silva, Célia R. G; Jorge, Antonio O. C; Hirtsch, Iracema M. V.
Rev. bras. hematol. hemoter ; 26(4): 285-287, out.-dez. 2004. ilus
Artículo en Portugués | LILACS | ID: lil-398134

Documentos relacionados

  1. Reconsidering Routine Repeat Group and Screens During Pregnancy-Personalizing Pregnancy Care.
  2. Following targeted routine antenatal anti-D prophylaxis, almost half of the pregnant women had undetectable anti-D prophylaxis at delivery.
  3. Perinatal outcomes and survival predictors of severe red-cell alloimmunization treated by intrauterine transfusion.
  4. Directive clinique n<sup>o</sup> 448 : Prévention de l'allo-immunisation Rhésus D.
  5. Risk factors for RhD immunisation in a high coverage prevention programme of antenatal and postnatal RhIg: a nationwide cohort study.
  6. Rh(D) immune globulin administration in pregnancy: Retrospective audit of patient safety events followed by targeted educational intervention with Bayesian analysis.
  7. Anti-RH1 alloimmunization: At what maternal antibody threshold is there a risk of severe fetal anemia?
  8. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
  9. Guideline No. 448: Prevention of Rh D Alloimmunization.
  10. The Norwegian experience with nationwide implementation of fetal RHD genotyping and targeted routine antenatal anti-D prophylaxis.